Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J E Herndon

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
Controlled Clinical Trials|September 19, 1998
A design alternative for two-stage, phase II, multicenter cancer clinical trialsJ E Herndon
Statistics in Medicine|October 15, 1995
The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariablesJ E Herndon, F E Harrell
Controlled Clinical Trials|August 1, 1997
A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931J E Herndon, S Fleishman, M P Kosty, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|April 1, 1994
A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B studyR H Wheeler, J E Herndon, G H Clamon, et al.
Cancer|December 26, 2001
Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screeningL E Heyneman, J E Herndon, P C Goodman, et al.
The Annals of Thoracic Surgery|May 1, 1996
Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancerD H Harpole, W G Richards, J E Herndon, et al.
Radiology|June 1, 2000
Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I diseaseM A Farrell, H P McAdams, J E Herndon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083M C Perry, J E Herndon, W L Eaton, et al.
British Journal of Cancer|September 28, 2006
Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenationG Vlahovic, Z N Rabbani, J E Herndon, et al.
American Journal of Clinical Oncology|February 1, 1995
A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGBJ D Bitran, M Green, M Perry, et al.
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Controlled Clinical Trials|September 19, 1998
A design alternative for two-stage, phase II, multicenter cancer clinical trialsJ E Herndon
Statistics in Medicine|October 15, 1995
The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariablesJ E Herndon, F E Harrell
Controlled Clinical Trials|August 1, 1997
A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931J E Herndon, S Fleishman, M P Kosty, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|April 1, 1994
A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B studyR H Wheeler, J E Herndon, G H Clamon, et al.
Cancer|December 26, 2001
Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screeningL E Heyneman, J E Herndon, P C Goodman, et al.
The Annals of Thoracic Surgery|May 1, 1996
Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancerD H Harpole, W G Richards, J E Herndon, et al.
Radiology|June 1, 2000
Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I diseaseM A Farrell, H P McAdams, J E Herndon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083M C Perry, J E Herndon, W L Eaton, et al.
British Journal of Cancer|September 28, 2006
Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenationG Vlahovic, Z N Rabbani, J E Herndon, et al.
American Journal of Clinical Oncology|February 1, 1995
A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGBJ D Bitran, M Green, M Perry, et al.
Pageof 9